Systematic Reviews and Meta- and Pooled Analyses Pelvic In fl ammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies

In fl ammation has been implicated in ovarian carcinogenesis. However, studies investigating the association between pelvic in fl ammatory disease (PID) and ovarian cancer risk are few and inconsistent. We investigated the association between PID and the risk of epithelial ovarian cancer according to tumor behavior and histotype. We pooled data from 13 case-control studies, conducted between 1989 and 2009, from the Ovarian Cancer Association Consortium (OCAC), including 9,162 women with ovarian cancers, 2,354 women with borderline tumors, and 14,736 control participants. Study-speci fi c odds ratios were estimated and subsequently combined into a pooled odds ratio using a random-effects model. A history of PID was associated with an increased risk of borderline tumors (pooled odds ratio (pOR) = 1.32, 95% con fi dence interval (CI): 1.10, 1.58). Women with at least 2 episodes of PID had a 2-fold increased risk of borderline tumors (pOR = 2.14, 95% CI: 1.08, 4.24). No association was observed between PID and ovarian cancer risk overall (pOR = 0.99, 95% CI: 0.83, 1.19); however, a statistically nonsigni fi cantly increased risk of low-grade serous tumors (pOR = 1.48, 95% CI: 0.92, 2.38) was noted. In conclusion, PID was associated with an increased risk of borderline ovarian tumors, particularly among women who had had multiple episodes of PID. Although our results indicated a histotype-speci fi c association with PID, the association of PID with ovarian cancer risk is still somewhat uncertain and requires further investigation.

[1]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[2]  J. McAlpine,et al.  Pelvic Inflammation and the Pathogenesis of Ovarian Cancer: A Cohort Study , 2014, International Journal of Gynecologic Cancer.

[3]  Yurii B. Shvetsov,et al.  Genital Powder Use and Risk of Ovarian Cancer: A Pooled Analysis of 8,525 Cases and 9,859 Controls , 2013, Cancer Prevention Research.

[4]  A. Chandra,et al.  Correlates of Self-Reported Pelvic Inflammatory Disease Treatment in Sexually Experienced Reproductive-Aged Women in the United States, 1995 and 2006–2010 , 2013, Sexually transmitted diseases.

[5]  S. Kjaer,et al.  Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors , 2013, Cancer Causes & Control.

[6]  S. Schüler,et al.  Ovarian epithelial tumors and reproductive factors: a systematic review , 2013, Archives of Gynecology and Obstetrics.

[7]  Russell Vang,et al.  Fallopian tube precursors of ovarian low‐ and high‐grade serous neoplasms , 2013, Histopathology.

[8]  Sun exposure and risk of epithelial ovarian cancer , 2012, Cancer Causes & Control.

[9]  S. Tworoger,et al.  Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis , 2012, Journal of Ovarian Research.

[10]  M. Pike,et al.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.

[11]  L. Kiemeney,et al.  Adequacy of family history taking in ovarian cancer patients: a population-based study , 2012, Familial Cancer.

[12]  C. Bunker,et al.  Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drugs, or Acetaminophen and Risk of Ovarian Cancer , 2012, Epidemiology.

[13]  S. Olson,et al.  Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study , 2011, BMC women's health.

[14]  W. Su,et al.  Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. , 2011, The Lancet. Oncology.

[15]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[16]  Barry Rosen,et al.  Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. , 2011, Gynecologic oncology.

[17]  Jeffrey R. Marks,et al.  Association between DNA Damage Response and Repair Genes and Risk of Invasive Serous Ovarian Cancer , 2010, PloS one.

[18]  B. Rosner,et al.  Risk factors for epithelial ovarian cancer by histologic subtype. , 2010, American journal of epidemiology.

[19]  Jinsong Liu,et al.  Inflammation: A hidden path to breaking the spell of ovarian cancer , 2009, Cell cycle.

[20]  M. Pike,et al.  Markers of inflammation and risk of ovarian cancer in Los Angeles County , 2009, International journal of cancer.

[21]  A. Parwani Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma , 2009 .

[22]  M. Goodman,et al.  Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk. , 2008, Endocrine-related cancer.

[23]  A. Whittemore,et al.  Consortium analysis of 7 candidate SNPs for ovarian cancer , 2008, International journal of cancer.

[24]  A. Green,et al.  Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer , 2008, International journal of cancer.

[25]  C. Harris,et al.  Inflammation and cancer: An ancient link with novel potentials , 2007, International journal of cancer.

[26]  L. Kiemeney,et al.  Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. , 2007, Kidney international.

[27]  H. Risch,et al.  PGR +331 A/G and Increased Risk of Epithelial Ovarian Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[28]  M. S. St. Louis,et al.  Trends in Pelvic Inflammatory Disease Hospital Discharges and Ambulatory Visits, United States, 1985–2001 , 2005, Sexually transmitted diseases.

[29]  L. Westrom Decrease in incidence of women treated in hospital for acute salpingitis in Sweden , 2005 .

[30]  J. Ross Pelvic inflammatory disease. , 2005, Clinical evidence.

[31]  B. Thomsen,et al.  Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. , 2004, Archives of internal medicine.

[32]  M. Pike,et al.  Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. , 2004, Fertility and sterility.

[33]  Michal Abrahamowicz,et al.  Modeling smoking history: a comparison of different approaches. , 2002, American journal of epidemiology.

[34]  E Demidenko,et al.  Two‐stage methods for the analysis of pooled data , 2001, Statistics in medicine.

[35]  M. Morgan,et al.  Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. , 2000, Epidemiology.

[36]  D. Seminara,et al.  Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  R. Ness,et al.  Possible role of ovarian epithelial inflammation in ovarian cancer. , 1999, Journal of the National Cancer Institute.

[38]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[39]  C. la Vecchia,et al.  Pelvic inflammatory disease and risk of ovarian cancer. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[40]  H. Risch,et al.  Pelvic inflammatory disease and the risk of epithelial ovarian cancer. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  H. Risch,et al.  Dietary fat intake and risk of epithelial ovarian cancer. , 1994, Journal of the National Cancer Institute.

[42]  X. Shu,et al.  Population-based case-control study of ovarian cancer in Shanghai. , 1989, Cancer research.

[43]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[44]  W. Cates,et al.  Self-reported pelvic inflammatory disease in the US: a common occurrence. , 1985, American journal of public health.

[45]  D. Cramer,et al.  Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. , 1983, Journal of the National Cancer Institute.

[46]  M F Fathalla,et al.  Incessant ovulation--a factor in ovarian neoplasia? , 1971, Lancet.

[47]  Fathalla Mf Incessant ovulation--a factor in ovarian neoplasia? [letter] , 1971 .

[48]  F. Massey The Kolmogorov-Smirnov Test for Goodness of Fit , 1951 .